CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
CRA adds Kevin Williams, Yale School of Management Professor, as academic affiliate to Antitrust Practice
“I am pleased to welcome Kevin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Kevin is a recognized expert in...